MicroRNA and non-canonical TGF-β signalling: Implications for prostate cancer therapy

Critical Reviews in Oncology/Hematology

Volumn 92, Issue 1, 2014, Pages 49-60

  Ottley, Edward ^a   Gold, Elspeth ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

MicroRNA; Prostate cancer; Smad signalling; TGF superfamily

Indexed keywords

GROWTH FACTOR; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; SIGNAL PEPTIDE;

ADVANCED CANCER; CANCER GROWTH; CANCER THERAPY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CANCER STAGING; DISEASE COURSE; GENETICS; MALE; METABOLISM; PROSTATIC NEOPLASMS;

ANIMALS; DISEASE PROGRESSION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICRORNAS; NEOPLASM STAGING; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84906938059     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.05.011     Document Type: Review

References (92)

1. Bill-Axelson A., Holmberg L., Ruutu M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011, 364:1708-1717.
2. Harris W.P., Mostaghel E.A., Nelson P.S., Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009, 6:76-85.
3. Hsing A.W., Devesa S.S. Trends and patterns of prostate cancer: what do they suggest. Epidemiol Rev 2001, 12:3-13.
4. Guichard G., Larré S., Gallina A., et al. Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol 2007, 52:430-435.
5. Razi A. Prostate cancer screening, yes or no? The current controversy. Urol J 2009, 1:240-245.
6. Andriole G.L., Grubb R.L., Buys S.S., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360:1310-1319.
7. Lin K., Lipsitz R., Miller T., Janakiraman S. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the US Preventive Services Task Force. Ann Intern Med 2008, 149:192.
8. Perlmutter M.A., Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol 2007, 9:S1-S8.
9. Evan Y.Y., Gulati R., Telesca D., et al. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol 2010, 28:2668-2673.
10. Petrylak D.P. Future directions in the treatment of androgen-independent prostate cancer. Urology 2005, 65:8-12.
11. Santibanez J.F., Quintanilla M., Bernabeu C. TGF-beta/TGF-beta receptor system and its role in physiological and pathological conditions. Clin Sci 2011, 121:233-251.
12. Butler C., Gold E., Risbridger G. Should activin C be more than a fading snapshot in the activin/TGF family album. Cytokine Growth Factor Rev 2005, 16:377-385.
13. Mehra A., Wrana J.L. TGF- and the Smad signal transduction pathway. Biochem Cell Biol 2002, 80:605-622.
14. Bai S., Cao X. A nuclear antagonistic mechanism of inhibitory Smads in transforming growth factor-signaling. J Biol Chem 2002, 277:4176.
15. Hanahan D., Weinberg Robert A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
16. Ottley E., Gold E. Insensitivity to the growth inhibitory effects of activin A: an acquired capability in prostate cancer progression. Cytokine Growth Factor Rev 2012, 23:119-125.
17. Risbridger G., Mellor S., McPherson S., Schmitt J. The contribution of inhibins and activins to malignant prostate disease. Mol Cell Endocrinol 2001, 180:149-153.
18. Gold E., Jetly N., O'Bryan M.K., et al. Activin C antagonizes activin A in vitro and overexpression leads to pathologies in vivo. Am J Pathol 2009, 174:184-195.
19. Dalkin A., Gilrain J., Bradshaw D., Myers C. Activin inhibition of prostate cancer cell growth: selective actions on androgen-responsive LNCaP cells. Endocrinology 1996, 137:5230-5235.
20. Ide H., Yoshida T., Matsumoto N., et al. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 1997, 57:5022-5027.
21. Gold L.I. The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog 1998, 10:303-360.
22. Massague J., Cheifetz S., Laiho M., Ralph D., Weis F., Zentella A. Transforming growth factor-beta. Cancer Surv 1991, 12:81-103.
23. Vo B.T., Cody B., Cao Y., Khan S.A. Differential role of Sloan-Kettering Institute (Ski) protein in nodal and transforming growth factor-beta (TGF-β)-induced Smad signaling in prostate cancer cells. Carcinogenesis 2012, 33:2054-2064.
24. Chuang J.C., Jones P.A. Epigenetics and microRNAs. Pediatr Res 2007, 61:24R-29R.
25. Sun K., Lai E.C. Adult-specific functions of animal microRNAs. Nat Rev Genet 2013, 14:535-548.
26. Coppola V., De Maria R., Bonci D. MicroRNAs and prostate cancer. Endocr Relat Cancer 2010, 17:F1-F17.
27. Hassan O., Ahmad A., Sethi S., Sarkar F.H. Recent updates on the role of microRNAs in prostate cancer. J Hematol Oncol 2012, 2012.
28. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854.
29. Wightman B., Ha I., Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993, 75:855-862.
30. Reinhart B.J., Slack F.J., Basson M., et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000, 403:901-906.
31. Catto J.W.F., Alcaraz A., Bjartell A.S., et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 2011, 59:671-681.
32. Kim V.N. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005, 6:376-385.
33. Martello G., Zacchigna L., Inui M., et al. MicroRNA control of Nodal signalling. Nature 2007, 449:183-188.
34. Senanayake U., Das S., Vesely P., et al. miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. Carcinogenesis 2012, 33:1014-1021.
35. Wang Q., Huang Z., Xue H., et al. MicroRNA miR-24 inhibits erythropoiesis by targeting activin type I receptor ALK4. Blood 2008, 111:588-595.
36. Zhang Q., Sun H., Jiang Y., et al. MicroRNA-181a Suppresses Mouse Granulosa Cell Proliferation by Targeting Activin Receptor IIA. PloS ONE 2013, 8:e59667.
37. Davis B.N., Hilyard A.C., Lagna G., Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008, 454:56-61.
38. Davis B.N., Hilyard A.C., Nguyen P.H., Lagna G., Hata A. Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. Mol Cell 2010, 39:373-384.
39. Davis-Dusenbery B.N., Hata A. Smad-mediated miRNA processing: a critical role for a conserved RNA sequence. RNA Biol 2011, 8:71-76.
40. Blahna M.T., Hata A. Smad-mediated regulation of microRNA biosynthesis. FEBS Lett 2012, 586:1906-1912.
41. Louafi F., Martinez-Nunez R.T., Sanchez-Elsner T. MicroRNA-155 targets SMAD2 and modulates the response of macrophages to transforming growth factor-β. J Biol Chem 2010, 285:41328-41336.
42. Wang Y., Ren J., Gao Y., et al. MicroRNA-224 targets SMAD family member 4 to promote cell proliferation and negatively influence patient survival. PloS ONE 2013, 8:e68744.
43. Mavridis K., Stravodimos K., Scorilas A. Downregulation and prognostic performance of microRNA 224 expression in prostate cancer. Clin Chem 2013, 59:261-269.
44. Yao G., Yin M., Lian J., et al. MicroRNA-224 is involved in transforming growth factor-β-mediated mouse granulosa cell proliferation and granulosa cell function by targeting Smad4. Mol Endocrinol 2010, 24:540-551.
45. Fellenberg J., Saehr H., Lehner B., Depeweg D. A microRNA signature differentiates between giant cell tumor derived neoplastic stromal cells and mesenchymal stem cells. Cancer Lett 2012, 321:162-168.
46. Liu G., Friggeri A., Yang Y., et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010, 207:1589-1597.
47. Zhang Y.E. Non-Smad pathways in TGF-β signaling. Cell Res 2008, 19:128-139.
48. Mu Y., Gudey S.K., Landström M. Non-Smad signaling pathways. Cell Tissue Res 2012, 347:11-20.
49. Butz H., Rácz K., Hunyady L., Patócs A. Crosstalk between TGF-β signaling and the microRNA machinery. Trends Pharmacol Sci 2012, 33:382-393.
50. Moustakas A., Heldin C-H. Non-Smad TGF-β signals. J Cell Sci 2005, 118:3573-3584.
51. da Silva H.B., Amaral E.P., Nolasco E.L., et al. Dissecting major signaling pathways throughout the development of prostate cancer. Prostate Cancer 2013, 2013:1-23.
52. Treiber T., Meister G. Smads stimulate mirna processing. Mol Cell 2010, 39:315-316.
53. Hata A., Davis B.N. Control of microRNA biogenesis by TGFβ signaling pathway-a novel role of Smads in the nucleus. Cytokine Growth Factor Rev 2009, 20:517-521.
54. Kohno M., Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. Ann Med 2006, 38:200-211.
55. Boucher M-J., Morisset J., Vachon P.H., Reed J.C., Lainé J., Rivard N. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-XL, and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 2000, 79:355-369.
56. Krysan K., Reckamp K.L., Dalwadi H., et al. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 2005, 65:6275-6281.
57. Price D.T., Rocca G.D., Guo C., Ballo M.S., Schwinn D.A., Luttrell L.M. Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol 1999, 162:1537-1542.
58. Zelivianski S., Spellman M., Kellerman M., et al. ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer 2003, 107:478-485.
59. Kinkade C.W., Castillo-Martin M., Puzio-Kuter A., et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Investig 2008, 118:3051.
60. Yoshida B.A., Dubauskas Z., Chekmareva M.A., Christiano T.R., Stadler W.M., Rinker-Schaeffer C.W. Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res 1999, 59:5483-5487.
61. Matsuura I., Wang G., He D., Liu F. Identification and characterization of ERK MAP kinase phosphorylation sites in Smad3. Biochemistry 2005, 44:12546-12553.
62. Kretzschmar M., Doody J., Timokhina I., Massagué J. A mechanism of repression of TGFβ/Smad signaling by oncogenic Ras. Genes Dev 1999, 13:804-816.
63. Clapé C., Fritz V., Henriquet C., et al. miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PloS ONE 2009, 4:e7542.
64. Ramsay A., McCracken S., Soofi M., et al. ERK5 signalling in prostate cancer promotes an invasive phenotype. Br J Cancer 2011, 104:664-672.
65. Dudderidge T., McCracken S., Loddo M., et al. Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer. Br J Cancer 2007, 96:1384-1393.
66. Ahmad I., Singh L., Yang Z., et al. Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer. Br J Cancer 2013, 108:149-154.
67. Porkka K.P., Pfeiffer M.J., Waltering K.K., Vessella R.L., Tammela T.L.J., Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007, 67:6130.
68. Tong A., Fulgham P., Jay C., et al. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 2009, 16:206-216.
69. Hough C., Radu M., Doré J.J. Tgf-beta induced Erk phosphorylation of smad linker region regulates smad signaling. PLoS ONE 2012, 7:e42513.
70. Xu B., Niu X., Zhang X., et al. miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem 2011, 350:207-213.
71. De Wever O., Nguyen Q-D., Van Hoorde L., et al. Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J 2004, 18:1016-1018.
72. Pillé J-Y., Denoyelle C., Varet J., et al. Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther 2005, 11:267-274.
73. Kamai T., Yamanishi T., Shirataki H., et al. Overexpression of RhoA, Rac1, and Cdc42 GTPases is associated with progression in testicular cancer. Clin Cancer Res 2004, 10:4799-4805.
74. Hodge J.C., Bub J., Kaul S., Kajdacsy-Balla A., Lindholm P.F. Requirement of RhoA activity for increased nuclear factor (B activity and PC-3 human prostate cancer cell invasion. Cancer Res 2003, 63:1359-1364.
75. Lee J., Lee I., Park C., Kang W.K. Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells. Biochem Biophys Res Commun 2006, 339:748-754.
76. Ghosh P.M., Bedolla R., Mikhailova M., Kreisberg J.I. RhoA-dependent murine prostate cancer cell proliferation and apoptosis role of protein kinase Cζ. Cancer Res 2002, 62:2630-2636.
77. Grünert S., Jechlinger M., Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 2003, 4:657-665.
78. Kong W., Yang H., He L., et al. MicroRNA-155 is regulated by the transforming growth factor β/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol 2008, 28:6773-6784.
79. Edlund S., Landström M., Heldin C-H., Aspenström P. Smad7 is required for TGF-β-induced activation of the small GTPase Cdc42. J Cell Sci 2004, 117:1835-1847.
80. Yilmaz M., Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009, 28:15-33.
81. Somlyo A.V., Bradshaw D., Ramos S., Murphy C., Myers C.E., Somlyo A.P. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun 2000, 269:652-659.
82. Thomas G.V., Horvath S., Smith B.L., et al. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res 2004, 10:8351-8356.
83. Ayala G., Thompson T., Yang G., et al. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 2004, 10:6572-6578.
84. Lee K-H., Chen Y-L., Yeh S., et al. MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene 2009, 28:3360-3370.
85. Cimmino A., Calin G.A., Fabbri M., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005, 102:13944-13949.
86. Ambs S., Prueitt R.L., Yi M., et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008, 68:6162-6170.
87. Chen K-F., Yu H-C., Liu T-H., Lee S-S., Chen P-J., Cheng A-L. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J Hepatol 2010, 52:88-95.
88. Du K., Tsichlis P.N. Regulation of the Akt kinase by interacting proteins. Oncogene 2005, 24:7401-7409.
89. Hamano R., Miyata H., Yamasaki M., et al. Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res 2011, 17:3029-3038.
90. Li X., Lin R., Li J. Epigenetic silencing of microRNA-375 regulates PDK1 expression in esophageal cancer. Dig Dis Sci 2011, 56:2849-2856.
91. Ge Y., Pan S., Guan D., et al. MicroRNA-350 induces pathological heart hypertrophy by repressing both p38 and JNK pathways. Biochim Biophys Acta 2012, 1-10.
92. Wang Y., Li W., Zang X., et al. MicroRNA-204-5p regulates epithelial-to-mesenchymal transition during human posterior capsule opacification by targeting SMAD4. Invest Ophthalmol Vis Sci 2013, 54:323-332.